8-K current report · filed Nov 5, 2026

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) 8-K Current Report: November 5, 2026

Item EX-99.1Item 8.01IOVA overview

Short answer

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 8.01 (Other Events). Updated corporate presentation signals refreshed messaging for healthcare conferences, analysts, and investors.

IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Updated corporate presentation signals refreshed messaging for healthcare conferences, analysts, and investors
  • Exhibit 99.1 contains the substantive investor materials and should be reviewed for pipeline, clinical, or commercial updates

Item EX-99.1 · Exhibit EX-99.1

  • 3Q26 revenue ~$382M, up ~80% YoY and ~22% QoQ, demonstrating accelerating Amtagvi commercial adoption
  • Full-year 2026 revenue guidance $410M-$420M, midpoint up $55M or ~15% versus prior guidance of $350M-$370M
  • Cash ~$382M with runway well into 2029, reducing near-term financing pressure while pipeline programs advance
  • NSCLC data showed 24.6% ORR overall and 59% ORR in biomarker-enriched patients, supporting planned 2027 sBLA submission
  • Commercial infrastructure exceeded 100 ATCs across the U.S., Canada and Australia, with 5K+ annual manufacturing capacity supporting expansion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings

Get the next IOVA 8-K as it lands

Follow IOVA for push alerts, or ask the research agent what this filing means.